Saturday, May 31, 2025

Latest

Curaleaf: Haywood Reiterates $22 Price Target, Names Firm A Top Pick For 2022

On December 28th, Curaleaf Holdings (CSE: CURA) announced that they have entered into a definitive agreement to acquire Bloom Dispensaries for roughly US$211 million in cash, with $50 million being paid at the closing date, and $50/$50/$60 million on the first, second and third anniversary of the closing date. The deal is expected to close in January of 2022 and Curaleaf expects it to be immediately accretive to adjusted EBITA.

Curaleaf currently has 15 analysts covering the stock with an average 12-month price target of C$24.80, or a 135% upside to the current stock price. Out of the 15 analysts, 5 have strong buy ratings, 9 have buy ratings and 1 analyst has a hold rating on the stock. The street high sits at C$31 from Stifel-GMP while the lowest 12-month price target comes in at C$20.

In Haywood Capital Markets’ note, they reiterate their C$22 12-month price target and buy rating, saying that this and the other recently announced acquisitions are an efficient use of proceeds. Bloom Dispensaries operates a 63,500 square foot cultivation and processing facility in Arizona, as well as several dispensaries. Haywood expects that the state of Arizona will do a combined $1.3 billion in sales for 2021.

Haywood says that Bloom is expected to do roughly $66 million in full-year revenue with adjusted EBITDA margins of >40%, so they have Bloom being acquired at a 3.2x 2021 and 8.0x 2021 revenue and adjusted EBITDA multiple. They also say that Arizona has continued to have a strong medical program while the adult-use program hit a new sales high in October. They believe that the market will grow faster than analysts’ expectations of $760 in adult-use sales by year four, as the state has done roughly $400 million this year alone.

Lastly, Haywood reiterates Curaleaf as their top pick in the cannabis sector, saying that it, “remains well-positioned with the largest state footprint.” They believe that this acquisition and the most recent debt financing will help Curaleaf expand its margins in 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

New Found Gold: BMO Initiates With $10 Price Target

BMO Capital Markets this week initiated coverage on New Found Gold (TSXV: NFG) with an...

Thursday, June 9, 2022, 11:02:00 AM

Galaxy Digital: BMO Cuts Price Target To $16 After Crypto Crash

On Monday, Galaxy Digital Holdings Ltd. (TSX: GLXY) reported its second quarter financial results. The...

Thursday, August 11, 2022, 11:36:00 AM

Uber: Analysts Expect Q1 Net Income To Approach Negative $1 Billion

Uber (NYSE: UBER) will be reporting its first quarter financial results today after market close....

Wednesday, May 5, 2021, 02:44:00 PM

Zoom: Analysts Anticipate $906 Million In Q1 Revenues

Zoom Video Communications (NASDAQ: ZM) will be reporting their first quarter financial results June 1st...

Tuesday, June 1, 2021, 11:21:00 AM

Canaccord: Canopy USA Transaction Is An Overall Positive

Canopy Growth (TSX: WEED) earlier this week revealed that it would be restructuring its US...

Thursday, October 27, 2022, 03:06:00 PM